MPI-2 Stuttering Treatment is a clinical biofeedback tool for speech therapy that connects users with certified pathologists on iOS.
Product velocity
Dormant
Daily rank 🇺🇸
—
Medical
Sentiment
3.6
5 reviews
Nemesis
Fragmented field
The App DNA
What makes this app unique?
The platform removes the need for in-clinic monitoring by allowing patients to practice speech patterns remotely while maintaining professional oversight.
For Adolescents and adults who stutter seeking professional, evidence-based speech therapy.
What does it look like?
Key features
Tracks phonation intervals via throat microphone and accelerometer hardware to provide real-time speech data.
Connects users with certified speech-language pathologists for professional evaluation and treatment.
How much does it cost?
The application is free to install, but clinical services are billed directly by the chosen speech-language pathologist.
Velocity
Dormant developmentopaqueShow more...
Development has ceased, with no updates or feature releases recorded in the last 695 days. The latest release provided only generic bug fixes and optimizations before the project entered a period of total inactivity. There is no evidence of ongoing maintenance or support for the platform.
Who built it?
Sirma Medical Systems JSC
3 apps tracked · Medical
Diabetes:M
Medrec:MUser Sentiment
What do users think recently?
Review voice lately leans upset.
How are ratings & reviews evolving?
What users say, by theme
- Mandatory registration and clinician search requirements create significant friction for new users attempting to access the app
1 of 1 recent reviews analyzed · limited sample
Read the full review analysisCompetition
Competitive landscape for MPI-2 Stuttering Treatment
How's the Medical market?
MPI-2 Stuttering Treatment operates as a niche medical utility with a 3.6-star rating across a limited sample. The reliance on professional clinician matching differentiates the service from self-guided speech apps, though the 23-month update gap limits its competitive standing.
The rivals identified
The Analyst's Read
Key takeaways for MPI-2 Stuttering Treatment
Where is it heading?
The digital health market is shifting toward self-guided, agile therapy tools that provide immediate value without professional gatekeeping. MPI-2 Stuttering Treatment remains exposed due to its reliance on a high-friction, clinician-led model that has not seen a feature update in nearly two years.
- The 23-month update gap indicates a maintenance-only posture, which risks losing relevance to more frequently updated digital health competitors.
The SWOT
- Evidence-based clinical protocol developed by researchers
- Biofeedback hardware provides objective speech metrics
- Expansion into remote tele-therapy markets
Next best moves
Audit onboarding flow to allow guest access because mandatory registration is the top user complaint → reduce churn.
The counter-intuitive read
The lack of updates is not a failure…
Read the full takeSince the last report: The application has undergone no material changes, maintaining its status as a static clinical tool with no feature updates or shifts in market positioning over the last 695 days.
Bottom line
MPI-2 Stuttering Treatment rests on a validated clinical protocol, but the high-friction onboarding and lack of recent development limit its reach. Simplifying the entry path would unlock the funnel for users seeking immediate speech-therapy support.
Unlock 2 critical frictions, 1 market threat and the analyst’s take.
Access the full report for freeSources
- [1] App Store, source
Report last updated